NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
anti-CD73 monoclonal antibody TJ4309
A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody TJ4309 targets and binds to CD73 on tumor cells, thereby inhibiting CD73 activity. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment (TME). Check for active clinical trials using this agent. (NCI Thesaurus)

Code name:TJ 004309
TJ 4309
TJ004309
TJ-004309
TJ4309
TJ-4309
TJD5